CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,044,529 | +748.4% | 304,120 | +414.1% | 0.01% | +1100.0% |
Q2 2023 | $1,066,063 | +12.9% | 59,160 | +0.6% | 0.00% | 0.0% |
Q1 2023 | $944,135 | +86.6% | 58,788 | +112.7% | 0.00% | 0.0% |
Q4 2022 | $505,885 | -99.9% | 27,644 | -39.2% | 0.00% | 0.0% |
Q3 2022 | $893,325,000 | +297.8% | 45,485 | +277.7% | 0.00% | – |
Q2 2022 | $224,583,000 | +160.8% | 12,042 | +207.0% | 0.00% | – |
Q1 2022 | $86,110,000 | -71.1% | 3,923 | -62.6% | 0.00% | – |
Q4 2021 | $297,850,000 | +106.3% | 10,484 | +52.9% | 0.00% | – |
Q3 2021 | $144,382,000 | +420.4% | 6,859 | +366.0% | 0.00% | – |
Q2 2021 | $27,747,000 | -50.1% | 1,472 | -59.6% | 0.00% | – |
Q1 2021 | $55,634,000 | -38.6% | 3,641 | -43.3% | 0.00% | – |
Q4 2020 | $90,544,000 | -12.2% | 6,417 | -2.5% | 0.00% | – |
Q3 2020 | $103,109,000 | +288.2% | 6,580 | +334.0% | 0.00% | – |
Q2 2020 | $26,560,000 | -47.6% | 1,516 | -56.0% | 0.00% | – |
Q1 2020 | $50,671,000 | +24.4% | 3,447 | +112.3% | 0.00% | – |
Q4 2019 | $40,746,000 | +72.8% | 1,624 | +3.6% | 0.00% | – |
Q3 2019 | $23,583,000 | -7.7% | 1,568 | +53.4% | 0.00% | – |
Q2 2019 | $25,550,000 | -39.3% | 1,022 | -44.7% | 0.00% | – |
Q1 2019 | $42,060,000 | – | 1,848 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |